Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
NCT ID: NCT04964934
Last Updated: 2025-12-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
315 participants
INTERVENTIONAL
2021-06-30
2027-11-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This trial will look at six drugs: palbociclib, abemaciclib, ribociclib, letrozole, anastrozole, and AZD9833. AZD9833 is the trial drug, and is the only drug not yet approved for use. Palbociclib, abemaciclib and ribociclib work in the same way and are a type of cancer drug called a CDK4/6 inhibitor. Letrozole and anastrozole work in the same way and are both a type of cancer drug called an aromatase inhibitor (AI). CDK4/6 inhibitors and AIs work together to block the tumor's ability to grow. These drugs have been approved for combined use in people with advanced breast cancer that is HR-positive and HER2-negative. But if people get mutations in the ESR1 gene, it can make the AI and CDK4/6 inhibitor treatment work less well.
The trial drug, AZD9833, is designed to work with a CDK4/6 inhibitor in the same way that an AI does. Researchers think that AZD9833 might work better with a CDK4/6 inhibitor than an AI does in people who get mutations in their ESR1 gene.
Participants in this trial will have already been receiving one of the following combinations of a CDK4/6 inhibitor and an AI:
* palbociclib + anastrozole
* palbociclib + letrozole
* abemaciclib + anastrozole
* abemaciclib + letrozole
* ribociclib + anastrozole
* ribociclib + letrozole
During the trial, participants will remain on the same CDK4/6 inhibitor that they were taking before the trial.
In this trial, the researchers want to find out how well switching a participant with an ESR1 gene mutation from an AI (letrozole or anastrozole) to AZD9833 works in the treatment of advanced breast cancer that is HR-positive and HER2-negative.
The researchers will look at which trial treatment helps the participants live longer with the cancer before it gets worse.
The researchers also want to know more about how safe AZD9833 is.
The trial participants will be split into 2 groups:
* Participants in Group A will receive AZD9833, a CDK4/6 inhibitor, and a placebo
* Participants in Group B will receive an AI, a CDK4/6 inhibitor, and a placebo
A placebo looks like a treatment but does not have any medicine in it.
A computer program will be used to randomly choose the treatments each participant gets. This helps make sure the groups are chosen fairly. Researchers do this so that comparing the results of each treatment will be as accurate as possible.
The participants will take their trial treatments over 28-day cycles, with a placebo and either AZD9833 or an AI taken once daily by mouth for all 28 days. If the participant is taking abemaciclib, they will take it twice daily by mouth for all 28 days. If the participant is taking palbociclib or ribociclib, they will take it once daily by mouth for 21 days and then stop taking it for the final 7 days of the cycle. The participant will then repeat the 28-day cycle receiving the trial treatment in the same way for as long as they are in the trial.
Participants will visit their trial site regularly throughout the trial. At these visits, the trial doctors will check the health of the participants. They will also take blood samples and do scans of the participants' tumors.
Participants will take their trial treatment until their cancer gets worse or they decide to leave the trial.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AZD9833 + palbociclib, abemaciclib or ribociclib
The patients will receive AZD9833 (75 mg, PO, once daily) + palbociclib (PO, once daily, 125, 100 or 75 mg for 21 consecutive days followed by 7 days off treatment), abemaciclib (PO, twice daily, 150,100 or 50 mg) or ribociclib (To Be Determined, PO, once daily for 21 consecutive days followed by 7 days off treatment) + anastrozole placebo (PO, once daily) or letrozole placebo (PO, once daily)
AZD9833
Dosage formulation: AZD9833 tablets will be administered orally
Anastrozole placebo
Dosage formulation: anastrozole placebo tablets will be administrated orally.
Letrozole placebo
Dosage formulation: letrozole placebo tablets will be administered orally.
Palbociclib
Dosage formulation: palbociclib tablets/capsules will be administered orally
Abemaciclib
Dosage formulation: abemaciclib tablets will be administered orally
Luteinizing hormone-releasing hormone (LHRH) agonist
Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist.
Ribociclib
Dosage formulation: ribociclib tablets will be administered orally
Anastrozole or letrozole + palbociclib, abemaciclib or ribociclib
The patients will recieve anastrozole (1 mg, PO, once daily) or letrozole (2.5 mg, PO, once daily) + palbociclib (PO, once daily, 125, 100 or 75 mg for 21 consecutive days followed by 7 days off treatment), abemaciclib (PO, twice daily, 150, 100 or 50 mg) or ribociclib (To Be Determined, PO, once daily for 21 consecutive days followed by 7 days off treatment) + AZD9833 placebo (PO, once daily)
AZD9833 Placebo
Dosage formulation: AZD9833 placebo tablets will be administrated orally.
Anastrozole
Dosage formulation: anastrozole tablets will be administered orally.
Letrozole
Dosage formulation: letrozole tablets will be administered orally.
Palbociclib
Dosage formulation: palbociclib tablets/capsules will be administered orally
Abemaciclib
Dosage formulation: abemaciclib tablets will be administered orally
Luteinizing hormone-releasing hormone (LHRH) agonist
Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist.
Ribociclib
Dosage formulation: ribociclib tablets will be administered orally
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AZD9833
Dosage formulation: AZD9833 tablets will be administered orally
AZD9833 Placebo
Dosage formulation: AZD9833 placebo tablets will be administrated orally.
Anastrozole
Dosage formulation: anastrozole tablets will be administered orally.
Anastrozole placebo
Dosage formulation: anastrozole placebo tablets will be administrated orally.
Letrozole
Dosage formulation: letrozole tablets will be administered orally.
Letrozole placebo
Dosage formulation: letrozole placebo tablets will be administered orally.
Palbociclib
Dosage formulation: palbociclib tablets/capsules will be administered orally
Abemaciclib
Dosage formulation: abemaciclib tablets will be administered orally
Luteinizing hormone-releasing hormone (LHRH) agonist
Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist.
Ribociclib
Dosage formulation: ribociclib tablets will be administered orally
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have advanced breast cancer that is not able to be treated with surgery or radiation;
* Have an ESR1 mutation in their cancer;
* Have breast cancer that is HR-positive and HER2-negative;
* Are currently being treated with a CDK4/6 inhibitor and an AI and have been taking these drugs for at least 6 months;
* Have not had their cancer get worse after taking an AI and CDK4/6 inhibitor;
* Are able to do their daily activities;
* Are at least 18.
* Proven diagnosis of adenocarcinoma of the breast with evidence of locoregionally recurrent or metastatic disease not amenable to resection or radiation therapy with curative intent;
* Documentation of histologically confirmed diagnosis of estrogen receptor positive (ER+) /HER2- breast cancer based on local laboratory results;
* Currently on AI (letrozole or anastrozole) + CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) ± LHRH as the initial endocrine based treatment for advanced disease;
* Eastern Cooperative Oncology Group performance status of 0 or 1;
* ESR1m detected by central testing of ctDNA with Guardant360® CDx;
* Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures;
* Adequate organ and marrow function.
Exclusion Criteria
* Had certain types of tumors in the past that may come back;
* Are currently taking any other treatments for their cancer or other conditions including hormone replacements, medications, or supplements that could interfere with the trial treatment;
* Have or have had any major health problem, infection, or recent surgery that could make it difficult or dangerous to participate in this trial.
* Advanced, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term;
* Known active uncontrolled or symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease;
* Any evidence of severe or uncontrolled systemic diseases which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol;
* Patient with known or family history of severe heart disease;
* Previous treatment with AZD9833, investigational SERDs or fulvestrant;
* Currently pregnant (confirmed with positive pregnancy test) or breastfeeding;
* Persistent non-haematological toxicities (CTCAE Grade \> 2) caused by CDK4/6 inhibitor and/or AI treatment.
18 Years
130 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Phoenix, Arizona, United States
Research Site
Hot Springs, Arkansas, United States
Research Site
Little Rock, Arkansas, United States
Research Site
Long Beach, California, United States
Research Site
San Diego, California, United States
Research Site
Santa Rosa, California, United States
Research Site
Grand Junction, Colorado, United States
Research Site
Lone Tree, Colorado, United States
Research Site
Fort Myers, Florida, United States
Research Site
Jacksonville, Florida, United States
Research Site
Jacksonville, Florida, United States
Research Site
St. Petersburg, Florida, United States
Research Site
Atlanta, Georgia, United States
Research Site
Atlanta, Georgia, United States
Research Site
Atlanta, Georgia, United States
Research Site
Park Ridge, Illinois, United States
Research Site
Fort Wayne, Indiana, United States
Research Site
Indianapolis, Indiana, United States
Research Site
Baltimore, Maryland, United States
Research Site
Boston, Massachusetts, United States
Research Site
Fairhaven, Massachusetts, United States
Research Site
Foxborough, Massachusetts, United States
Research Site
Milford, Massachusetts, United States
Research Site
South Weymouth, Massachusetts, United States
Research Site
Detroit, Michigan, United States
Research Site
Grand Rapids, Michigan, United States
Research Site
Rochester, Minnesota, United States
Research Site
Oxford, Mississippi, United States
Research Site
Kansas City, Missouri, United States
Research Site
St Louis, Missouri, United States
Research Site
Billings, Montana, United States
Research Site
Omaha, Nebraska, United States
Research Site
Camden, New Jersey, United States
Research Site
Ridgewood, New Jersey, United States
Research Site
Brooklyn, New York, United States
Research Site
East Syracuse, New York, United States
Research Site
New Hyde Park, New York, United States
Research Site
New York, New York, United States
Research Site
New York, New York, United States
Research Site
Shirley, New York, United States
Research Site
Goldsboro, North Carolina, United States
Research Site
Canton, Ohio, United States
Research Site
Cincinnati, Ohio, United States
Research Site
Columbus, Ohio, United States
Research Site
Portland, Oregon, United States
Research Site
Philadelphia, Pennsylvania, United States
Research Site
Pittsburgh, Pennsylvania, United States
Research Site
York, Pennsylvania, United States
Research Site
Greenville, South Carolina, United States
Research Site
West Columbia, South Carolina, United States
Research Site
Knoxville, Tennessee, United States
Research Site
Memphis, Tennessee, United States
Research Site
Nashville, Tennessee, United States
Research Site
Bedford, Texas, United States
Research Site
Dallas, Texas, United States
Research Site
Houston, Texas, United States
Research Site
Houston, Texas, United States
Research Site
Irving, Texas, United States
Research Site
Longview, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
Salt Lake City, Utah, United States
Research Site
Midlothian, Virginia, United States
Research Site
Norfolk, Virginia, United States
Research Site
Tacoma, Washington, United States
Research Site
Waukesha, Wisconsin, United States
Research Site
Birtinya, , Australia
Research Site
Darlinghurst, , Australia
Research Site
Graz, , Austria
Research Site
Innsbruck, , Austria
Research Site
Salzburg, , Austria
Research Site
Vienna, , Austria
Research Site
Leuven, , Belgium
Research Site
Liège, , Belgium
Research Site
Namur, , Belgium
Research Site
Haskovo, , Bulgaria
Research Site
Panagyurishte, , Bulgaria
Research Site
Pleven, , Bulgaria
Research Site
Plovdiv, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Calgary, Alberta, Canada
Research Site
Vancouver, British Columbia, Canada
Research Site
Ottawa, Ontario, Canada
Research Site
Lévis, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Québec, Quebec, Canada
Research Site
Avignon, , France
Research Site
Brest, , France
Research Site
Clermont-Ferrand, , France
Research Site
Dijon, , France
Research Site
Limoges, , France
Research Site
Lorient, , France
Research Site
Lyon, , France
Research Site
Marseille, , France
Research Site
Metz-Tessy, , France
Research Site
Nîmes, , France
Research Site
Paris, , France
Research Site
Rouen, , France
Research Site
Saint-Cloud, , France
Research Site
Saint-Herblain, , France
Research Site
Toulouse, , France
Research Site
Tours, , France
Research Site
Vandœuvre-lès-Nancy, , France
Research Site
Vantoux, , France
Research Site
Villejuif, , France
Research Site
Ansbach, , Germany
Research Site
Aschaffenburg, , Germany
Research Site
Augsburg, , Germany
Research Site
Bonn, , Germany
Research Site
Chemnitz, , Germany
Research Site
Dresden, , Germany
Research Site
Erlangen, , Germany
Research Site
Essen, , Germany
Research Site
Freiburg im Breisgau, , Germany
Research Site
Immenstadt im Allgäu, , Germany
Research Site
Koblenz, , Germany
Research Site
Leipzig, , Germany
Research Site
Mannheim, , Germany
Research Site
München, , Germany
Research Site
Paderborn, , Germany
Research Site
Ratingen, , Germany
Research Site
Ravensburg, , Germany
Research Site
Regensburg, , Germany
Research Site
Stade, , Germany
Research Site
Tübingen, , Germany
Research Site
Ulm, , Germany
Research Site
Budapest, , Hungary
Research Site
Budapest, , Hungary
Research Site
Miskolc, , Hungary
Research Site
Szekszárd, , Hungary
Research Site
Szolnok, , Hungary
Research Site
Zalaegerszeg, , Hungary
Research Site
Beersheba, , Israel
Research Site
Haifa, , Israel
Research Site
Jerusalem, , Israel
Research Site
Petah Tikva, , Israel
Research Site
Ramat Gan, , Israel
Research Site
Bergamo, , Italy
Research Site
Bologna, , Italy
Research Site
Florence, , Italy
Research Site
Meldola, , Italy
Research Site
Milan, , Italy
Research Site
Milan, , Italy
Research Site
Misterbianco, , Italy
Research Site
Napoli, , Italy
Research Site
Padua, , Italy
Research Site
Roma, , Italy
Research Site
Rozzano, , Italy
Research Site
Chiba, , Japan
Research Site
Chūōku, , Japan
Research Site
Hidaka-shi, , Japan
Research Site
Hirakata-shi, , Japan
Research Site
Kitaadachi-gun, , Japan
Research Site
Kōtoku, , Japan
Research Site
Kumamoto, , Japan
Research Site
Matsuyama, , Japan
Research Site
Nagoya, , Japan
Research Site
Nagoya, , Japan
Research Site
Niigata, , Japan
Research Site
Osaka, , Japan
Research Site
Osaka, , Japan
Research Site
Ota-shi, , Japan
Research Site
Sapporo, , Japan
Research Site
Shinagawa-ku, , Japan
Research Site
Shinjuku-ku, , Japan
Research Site
Takasaki-shi, , Japan
Research Site
Takatsuki-shi, , Japan
Research Site
Tsukuba, , Japan
Research Site
Yokohama, , Japan
Research Site
Drammen, , Norway
Research Site
Oslo, , Norway
Research Site
Bydgoszcz, , Poland
Research Site
Gdynia, , Poland
Research Site
Koszalin, , Poland
Research Site
Lodz, , Poland
Research Site
Poznan, , Poland
Research Site
Rzeszów, , Poland
Research Site
Tomaszów Mazowiecki, , Poland
Research Site
Warsaw, , Poland
Research Site
Guimarães, , Portugal
Research Site
Lisbon, , Portugal
Research Site
Lisbon, , Portugal
Research Site
Lisbon, , Portugal
Research Site
Lisbon, , Portugal
Research Site
Loures, , Portugal
Research Site
Porto, , Portugal
Research Site
Porto, , Portugal
Research Site
Porto, , Portugal
Research Site
Vila Nova de Gaia, , Portugal
Research Site
Moscow, , Russia
Research Site
Moscow, , Russia
Research Site
Moscow, , Russia
Research Site
Nizhny Novgorod, , Russia
Research Site
Podolsk, , Russia
Research Site
Saint Petersburg, , Russia
Research Site
Saint Petersburg, , Russia
Research Site
Banská Bystrica, , Slovakia
Research Site
Bratislava, , Slovakia
Research Site
Košice, , Slovakia
Research Site
Michalovce, , Slovakia
Research Site
Partizánske, , Slovakia
Research Site
Cheonan-si, , South Korea
Research Site
Daegu, , South Korea
Research Site
Goyang-si, , South Korea
Research Site
Seongnam-si, , South Korea
Research Site
Seongnam-si, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
A Coruña, , Spain
Research Site
Badalona, , Spain
Research Site
Barcelona, , Spain
Research Site
L'Hospitalet de Llobregat, , Spain
Research Site
Madrid, , Spain
Research Site
Madrid, , Spain
Research Site
Málaga, , Spain
Research Site
Murcia, , Spain
Research Site
Sant Joan Despí, , Spain
Research Site
Seville, , Spain
Research Site
Valencia, , Spain
Research Site
Bern, , Switzerland
Research Site
Chur, , Switzerland
Research Site
Winterthur, , Switzerland
Research Site
Kaohsiung City, , Taiwan
Research Site
Taichung, , Taiwan
Research Site
Tainan, , Taiwan
Research Site
Tainan, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taoyuan District, , Taiwan
Research Site
Adana, , Turkey (Türkiye)
Research Site
Ankara, , Turkey (Türkiye)
Research Site
Ankara, , Turkey (Türkiye)
Research Site
Ankara, , Turkey (Türkiye)
Research Site
Ankara, , Turkey (Türkiye)
Research Site
Izmir, , Turkey (Türkiye)
Research Site
Izmir, , Turkey (Türkiye)
Research Site
Kadıkoy/Istanbul, , Turkey (Türkiye)
Research Site
Karşıyaka, , Turkey (Türkiye)
Research Site
Kayseri, , Turkey (Türkiye)
Research Site
Blackpool, , United Kingdom
Research Site
Cambridge, , United Kingdom
Research Site
London, , United Kingdom
Research Site
London, , United Kingdom
Research Site
Manchester, , United Kingdom
Research Site
Newport, , United Kingdom
Research Site
Nottingham, , United Kingdom
Research Site
Portsmouth, , United Kingdom
Research Site
Reading, , United Kingdom
Research Site
Sheffield, , United Kingdom
Research Site
Sutton, , United Kingdom
Research Site
Taunton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Bidard FC, Mayer EL, Park YH, Janni W, Ma C, Cristofanilli M, Bianchini G, Kalinsky K, Iwata H, Chia S, Fasching PA, Brufsky A, Nowecki Z, Pascual J, Moreau L, Chen SC, Karadurmus N, Gal-Yam EN, Jung KH, Pernas S, McClain S, He W, Klinowska T, Huang-Bartlett C, Turner NC; SERENA-6 Study Group. First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer. N Engl J Med. 2025 Aug 7;393(6):569-580. doi: 10.1056/NEJMoa2502929. Epub 2025 Jun 1.
Turner N, Huang-Bartlett C, Kalinsky K, Cristofanilli M, Bianchini G, Chia S, Iwata H, Janni W, Ma CX, Mayer EL, Park YH, Fox S, Liu X, McClain S, Bidard FC. Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. Future Oncol. 2023 Mar;19(8):559-573. doi: 10.2217/fon-2022-1196. Epub 2023 Apr 18.
Related Links
Access external resources that provide additional context or updates about the study.
Breast Cancer Study Locator details (for US)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D8534C00001
Identifier Type: -
Identifier Source: org_study_id
2023-503990-39-00
Identifier Type: OTHER
Identifier Source: secondary_id
2021-000546-17
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id